Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel Tanner

Showing results (51-60 of 79) with videos related to

Pageof 8
Sort By:
Frontiers in Immunology|August 5, 2025
MetE: a promising protective antigen for tuberculosis vaccine developmentSalem Salman Almujri, Elena Stylianou, Annalisa Nicastri, et al.
Nature Communications|November 4, 2022
Inflammation and immune activation are associated with risk of Mycobacterium tuberculosis infection in BCG-vaccinated infantsIman Satti, Rachel E Wittenberg, Shuailin Li, et al.
Vaccine|November 10, 2024
Intravenous BCG vaccination in non-human primates induces superior serum antibody titers with enhanced avidity and opsonizing capacity compared to the intradermal routeMarco Polo Peralta Alvarez, Keya Downward, Andrew White, et al.
BMC Infectious Diseases|December 4, 2014
Serum indoleamine 2,3-dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85ARachel Tanner, Kristina Kakalacheva, Ellen Miller, et al.
Scientific Reports|September 29, 2018
Immunological correlates of mycobacterial growth inhibition describe a spectrum of tuberculosis infectionMatthew K O'Shea, Rachel Tanner, Julius Müller, et al.
Tuberculosis (Edinburgh, Scotland)|March 11, 2018
Development of a non-human primate BCG infection model for the evaluation of candidate tuberculosis vaccinesStephanie A Harris, Andrew White, Lisa Stockdale, et al.
Clinical and Vaccine Immunology : CVI|May 16, 2014
Process of assay selection and optimization for the study of case and control samples from a phase IIb efficacy trial of a candidate tuberculosis vaccine, MVA85AStephanie A Harris, Iman Satti, Magali Matsumiya, et al.
Scientific Reports|May 13, 2022
Functional in-vitro evaluation of the non-specific effects of BCG vaccination in a randomised controlled clinical studyMorven Wilkie, Rachel Tanner, Daniel Wright, et al.
Frontiers in Immunology|January 9, 2019
Human Hookworm Infection Enhances Mycobacterial Growth Inhibition and Associates With Reduced Risk of Tuberculosis InfectionMatthew K O'Shea, Thomas E Fletcher, Julius Muller, et al.
Scientific Reports|March 4, 2017
The influence of haemoglobin and iron on in vitro mycobacterial growth inhibition assaysRachel Tanner, Matthew K O'Shea, Andrew D White, et al.
Pageof 8

Showing results (51-60 of 79) with videos related to

Sort By:
Pageof 8
Frontiers in Immunology|August 5, 2025
MetE: a promising protective antigen for tuberculosis vaccine developmentSalem Salman Almujri, Elena Stylianou, Annalisa Nicastri, et al.
Nature Communications|November 4, 2022
Inflammation and immune activation are associated with risk of Mycobacterium tuberculosis infection in BCG-vaccinated infantsIman Satti, Rachel E Wittenberg, Shuailin Li, et al.
Vaccine|November 10, 2024
Intravenous BCG vaccination in non-human primates induces superior serum antibody titers with enhanced avidity and opsonizing capacity compared to the intradermal routeMarco Polo Peralta Alvarez, Keya Downward, Andrew White, et al.
BMC Infectious Diseases|December 4, 2014
Serum indoleamine 2,3-dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85ARachel Tanner, Kristina Kakalacheva, Ellen Miller, et al.
Scientific Reports|September 29, 2018
Immunological correlates of mycobacterial growth inhibition describe a spectrum of tuberculosis infectionMatthew K O'Shea, Rachel Tanner, Julius Müller, et al.
Tuberculosis (Edinburgh, Scotland)|March 11, 2018
Development of a non-human primate BCG infection model for the evaluation of candidate tuberculosis vaccinesStephanie A Harris, Andrew White, Lisa Stockdale, et al.
Clinical and Vaccine Immunology : CVI|May 16, 2014
Process of assay selection and optimization for the study of case and control samples from a phase IIb efficacy trial of a candidate tuberculosis vaccine, MVA85AStephanie A Harris, Iman Satti, Magali Matsumiya, et al.
Scientific Reports|May 13, 2022
Functional in-vitro evaluation of the non-specific effects of BCG vaccination in a randomised controlled clinical studyMorven Wilkie, Rachel Tanner, Daniel Wright, et al.
Frontiers in Immunology|January 9, 2019
Human Hookworm Infection Enhances Mycobacterial Growth Inhibition and Associates With Reduced Risk of Tuberculosis InfectionMatthew K O'Shea, Thomas E Fletcher, Julius Muller, et al.
Scientific Reports|March 4, 2017
The influence of haemoglobin and iron on in vitro mycobacterial growth inhibition assaysRachel Tanner, Matthew K O'Shea, Andrew D White, et al.
Pageof 8